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Dual-channel imaging system for singlet oxygen
and photosensitizer for PDT
Seonkyung Lee,1,* Martin E. Isabelle,2 Kristin L. Gabally-Kinney,1 Brian W. Pogue,2,3
and Steven J. Davis1
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Thayer School of Engineering, Dartmouth College, 8000 Cummings Hall, Hanover, NH 03755, USA
3
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Abstract: A two-channel optical system has been developed to provide
spatially resolved simultaneous imaging of singlet molecular oxygen (1O2)
phosphorescence and photosensitizer (PS) fluorescence produced by the
photodynamic process. The current imaging system uses a spectral
discrimination method to differentiate the weak 1O2 phosphorescence that
peaks near 1.27 μm from PS fluorescence that also occurs in this spectral
region. The detection limit of 1O2 emission was determined at a
concentration of 500 nM benzoporphyrin derivative monoacid (BPD) in
tissue-like phantoms, and these signals observed were proportional to the PS
fluorescence. Preliminary in vivo images with tumor laden mice indicate
that it is possible to obtain simultaneous images of 1O2 and PS tissue
distribution.
©2011 Optical Society of America
OCIS codes: (170.0110) Imaging systems; (170.5180) Photodynamic therapy; (170.3880)
Medical and biological imaging.

References and links
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.

K. R. Weishaupt, C. J. Gomer, and T. J. Dougherty, “Identification of singlet oxygen as the cytotoxic agent in
photoinactivation of a murine tumor,” Cancer Res. 36(7 PT 1), 2326–2329 (1976).
A. C. Kubler, “Photodynamic Therapy,” Med. Laser Appl. 20(1), 37–45 (2005).
T. J. Farrell, R. P. Hawkes, M. S. Patterson, and B. C. Wilson, “Modeling of photosensitizer fluorescence
emission and photobleaching for photodynamic therapy dosimetry,” Appl. Opt. 37(31), 7168–7183 (1998).
S. L. Jacques, “Simple theory, measurements, and rules of thumb for dosimetry during photodynamic therapy,”
Proc. SPIE 1065, 100–108 (1989).
B. W. Pogue, R. D. Braun, J. L. Lanzen, C. Erikson, and M. W. Dewhirst, “Oxygen microelectrode
measurements in R3230Ac Tumors during photodynamic therapy with verteporfin,” Proc. SPIE 4248, 144
(2001).
B. W. Pogue, R. D. Braun, J. L. Lanzen, C. Erickson, and M. W. Dewhirst, “Analysis of the heterogeneity of pO2
dynamics during photodynamic therapy with verteporfin,” Photochem. Photobiol. 74(5), 700–706 (2001).
H. W. Wang, M. E. Putt, M. J. Emanuele, D. B. Shin, E. Glatstein, A. G. Yodh, and T. M. Busch, “Treatmentinduced changes in tumor oxygenation predict photodynamic therapy outcome,” Cancer Res. 64(20), 7553–7561
(2004).
D. Kessel, Y. Luo, P. Mathieu, and J. J. Reiners, Jr., “Determinants of the apoptotic response to lysosomal
photodamage,” Photochem. Photobiol. 71(2), 196–200 (2000).
V. H. Fingar, T. J. Wieman, S. A. Wiehle, and P. B. Cerrito, “The role of microvascular damage in photodynamic
therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion,” Cancer Res.
52(18), 4914–4921 (1992).
M. J. Niedre, M. S. Patterson, and B. C. Wilson, “Direct near-infrared luminescence detection of singlet oxygen
generated by photodynamic therapy in cells in vitro and tissues in vivo,” Photochem. Photobiol. 75(4), 382–391
(2002).
M. J. Niedre, C. S. Yu, M. S. Patterson, and B. C. Wilson, “Singlet oxygen luminescence as an in vivo
photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid,” Br. J.
Cancer 92(2), 298–304 (2005).
M. G. Nichols and T. H. Foster, “Oxygen diffusion and reaction kinetics in the photodynamic therapy of
multicell tumour spheroids,” Phys. Med. Biol. 39(12), 2161–2181 (1994).
S. Lee, L. Zhu, A. M. Minhaj, M. F. Hinds, D. H. Vu, D. I. Rosen, S. J. Davis, and T. Hasan, “Pulsed diode laserbased monitor for singlet molecular oxygen,” J. Biomed. Opt. 13(3), 034010 (2008).
S. Lee, D. H. Vu, M. F. Hinds, S. J. Davis, A. Liang, and T. Hasan, “Pulsed diode laser-based singlet oxygen
monitor for photodynamic therapy: in vivo studies of tumor-laden rats,” J. Biomed. Opt. 13(6), 064035 (2008).

#142278 - $15.00 USD

(C) 2011 OSA

Received 7 Feb 2011; revised 30 Mar 2011; accepted 13 Apr 2011; published 15 Apr 2011

1 May 2011 / Vol. 2, No. 5 / BIOMEDICAL OPTICS EXPRESS 1233

15. H. J. Laubach, S. K. Chang, S. Lee, I. Rizvi, D. Zurakowski, S. J. Davis, C. R. Taylor, and T. Hasan, “In-vivo
singlet oxygen dosimetry of clinical 5-aminolevulinic acid photodynamic therapy,” J. Biomed. Opt. 13(5),
050504 (2008).
16. L. K. Andersen, Z. Gao, P. R. Ogilby, L. Poulsen, and I. Zebger, “A Singlet oxygen image with 2.5 μm
resolution,” J. Phys. Chem. A 106(37), 8488–8490 (2002).
17. I. Zebger, J. W. Snyder, L. K. Andersen, L. Poulsen, Z. Gao, J. D. C. Lambert, U. Kristiansen, and P. R. Ogilby,
“Direct optical detection of singlet oxygen from a single cell,” Photochem. Photobiol. 79(4), 319–322 (2004).
18. M. J. Niedre, M. S. Patterson, A. Giles, and B. C. Wilson, “Imaging of photodynamically generated singlet
oxygen luminescence in vivo,” Photochem. Photobiol. 81(4), 941–943 (2005).
19. T. Breitenbach, M. K. Kuimova, P. Gbur, S. Hatz, N. B. Schack, B. W. Pedersen, J. D. C. Lambert, L. Poulsen,
and P. R. Ogilby, “Photosensitized production of singlet oxygen: spatially-resolved optical studies in single
cells,” Photochem. Photobiol. Sci. 8(4), 442–452 (2009).
20. Y. C. Wei, J. Zhou, D. Xing, and Q. Chen, “In vivo monitoring of singlet oxygen using delayed
chemiluminescence during photodynamic therapy,” J. Biomed. Opt. 12(1), 014002 (2007).
21. M. Price, J. J. Reiners, A. M. Santiago, and D. Kessel, “Monitoring singlet oxygen and hydroxyl radical
formation with fluorescent probes during photodynamic therapy,” Photochem. Photobiol. 85(5), 1177–1181
(2009).
22. B. Hu, N. Zeng, Z. Liu, Y. Ji, W. Xie, Q. Peng, Y. Zhou, Y. He, and H. Ma, “Two-dimensional singlet oxygen
imaging with its near-infrared luminescence during photosensitization,” J. Biomed. Opt. 16(1), 016003 (2011).
23. S. Lee, D. H. Vu, M. F. Hinds, S. J. Davis, J. A. O'Hara, and B. W. Pogue, “A singlet molecular oxygen imaging
sensor for photodynamic therapy,” in Biomedical Optics, OSA Technical Digest (CD) (Optical Society of
America, 2008), paper BTuC4.
24. S. Lee, K. L. Galbally-Kinney, B. A. Murphy, S. J. Davis, T. Hasan, B. Spring, Y. Tu, B. W. Pogue, M. E.
Isabelle, and J. A. O’Hara, “In vivo PDT dosimetry: singlet oxygen emission and photosensitizer fluorescence,”
Proc. SPIE 7551, 75510F (2010).
25. U. Schmidt-Erfurth and T. Hasan, “Mechanisms of action of photodynamic therapy with verteporfin for the
treatment of age-related macular degeneration,” Surv. Ophthalmol. 45(3), 195–214 (2000).
26. L. Ayaru, J. Wittmann, A. J. Macrobert, M. Novelli, S. G. Bown, and S. P. Pereira, “Photodynamic therapy using
verteporfin photosensitization in the pancreas and surrounding tissues in the Syrian golden hamster,”
Pancreatology 7(1), 20–27 (2007).
27. J. O’Hara, K. S. Samkoe, A. Chen, P. J. Hoopes, I. Rizvi, T. Hasan, and B. W. Pogue, “Uptake of verteporfin by
orthotopic xenograft pancreas models with different levels of aggression,” Proc. SPIE 7380, 73805F, 73805F-7
(2009).

1. Introduction
Photodynamic therapy (PDT) is a promising cancer treatment. It involves optical excitation of
photosensitizers that subsequently produces excited singlet molecular oxygen (1O2) via
collisional quenching by ground state oxygen molecules within the tumor tissue [1,2].
However, the tumor response to PDT treatments is highly variable depending on the
photosensitizer (PS) concentration in the tumor, treatment light intensity, total light dose
(fluence), and tumor oxygenation. An accurate dosimeter to optimize the individual treatment
response of PDT in a clinical environment would be a valuable tool to improve the treatment
outcomes. A number of groups have attempted to develop dosimeters based on the
fluorescence intensity of the PS in the tumor [3–5], but the complex dynamics of oxygenindependent photobleaching of the PS as well as photoproduct formation may preclude this as
an accurate method without careful calibration for each indication. Optical measurement of
the 1O2 phosphorescence produced in tissue would be a more direct way to assess PDT dose to
the tissue. It is well established that the PDT process consumes oxygen in a manner which can
substantially deplete the available oxygen supply within tumor tissues [6]. This effect is
unfavorable for maximal treatment response, as it results in decreased 1O2 production. It has
been suggested that maximizing the oxygenation of tissue can enhance PDT efficiency [7].
Our imaging system may be able to provide insight into this mechanism.
During the PDT treatment, oxygen molecules in the metastable singlet delta state, O2(a1Δ),
are generated and are believed to be responsible for the destruction of cancer cells [8,9]. The
1
O2 generation is related to the product of the PS concentration [PS], the molecular oxygen
concentration [O2], and the light dosage Φ(t), i.e. [1O2] ∝  [PS(t)] [O2] Φ(t) dt. There has been
considerable interest in developing a sensor for 1O2 that could be used as a real-time dosimeter
during PDT treatments [10–15]. Although the measurement of the 1O2 emission centered near
1.27 µm has the potential to be an effective technique for evaluating the PDT treatment
efficacy, monitoring only the 1O2 production does not distinguish whether the PDT efficacy is
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limited by oxygen availability or the localized tissue PS concentration. To address this issue,
we developed a two-dimensional (2D) imaging dosimeter system that enables simultaneous
imaging of both spatially resolved 1O2 phosphorescence and PS fluorescence. In 2002, a 1O2
image from a→X transition at 1270 nm with a lateral resolution of 2.5 μm was report by
Andersen et al. [16]. They used a microscope with a custom-made InGaAs linear array. The
sample was scanned with a movable x-y stage to generate 2D images. Several groups have
reported 1O2 images of a single cell and intradermal tumor model in mice by using scanningbased techniques [17–19]. Since the 1O2 emission signal is very weak at 1270 nm, chemically
trapped 1O2 detection methods in the visible wavelength region have also been reported
[20,21]. Recently, Hu et al. reported the images of the 1O2 emission with only using a 1.27 μm
optical filter with a cooled InGaAs CCD camera with detection limit of ~0.0181 μg/ml BPDMA in 75% ethanol [22]. They claimed that a long-pass filter (LP1150) was sufficient to
achieve spectral discrimination of the 1O2 emission from other possible radiations, such as PS
fluorescence, backscattered laser light, and autofluorescence from tissues in vivo.
The weak optical emission from 1O2 is one of the major challenges in developing an
optically-based monitor for this species. We have previously reported on an ultra-sensitive,
non-imaging sensor with a near-infrared (IR) sensitive photomultiplier tube (PMT) detector
for 1O2 measurements both in vitro and in vivo [13–15]. In those studies, a low power, pulsed
diode laser was used to produce the PDT photoreaction products and the optical emissions
were detected with a fast photon-counting system. Spectral and temporal discrimination
techniques were used to isolate the 1O2 phosphorescence from the PS fluorescence: (1)
spectral discrimination via a set of three optical filters (1.22, 1.27, and 1.32 μm), and (2) the
lifetime difference between short-lived PS fluorescence (a lifetime of the order of 10 ns) and
longer-lived 1O2 phosphorescence (lifetime of 4 μs in aqueous media and as short as 0.1 μs in
biological media) [13,14]. The 1.22 and 1.32 µm filters provide a measure of the PS
fluorescence and possible tissue fluorescence in this near infrared region, while the 1.27 µm
filter contains underlying continuum PS fluorescence, autofluorescence, and 1O2 near-IR
emission. We have successfully detected 1O2 phosphorescence in tumor laden mice and
healthy human skin [14,15]. In the animal study, a positive correlation was observed between
the 1O2 production and tumor regression.
In this study, we describe our early continuing progress in the development of the 2D
imaging configuration to produce spatial maps of the 1O2 phosphorescence and PS
fluorescence during PDT. The ability to obtain simultaneous images of both the PS and 1O2
will be valuable for assessing the relationship between PS bleaching and 1O2 production. In
addition, knowledge of the spatial extent of the tumor sites may help to target the tumor more
effectively without damaging healthy tissues. We have previously characterized the system
using in vitro samples with several photosensitizers (chlorine e6, δ-aminoleuvulinic acidinduced protoporphyrin IX, and benzoporphyrin derivative monoacid) in several media
including methanol, water, and fetal bovine serum (FBS), and intralipid solutions as well as
tumor laden mice [23,24]. Here, we report the results obtained with benzoporphyrin derivative
monoacid (BPD-MA) photosensitizer in methanol, water, FBS, and intralipid solutions. We
also present preliminary in vivo images with tumor laden mice.
2. Methods
2.1. Dual-channel imaging system configuration
Figure 1(a) shows a schematic of the 2D imaging system consisting of the excitation diode
laser, near-IR sensitive camera, and visible wavelength sensitive camera. The imaging system
is capable of simultaneous registration of images of 1O2 phosphorescence and PS fluorescence
in a time frame of a few minutes, compared with typical raster-scanning methods that take
tens of minutes to map out an entire area of interest. Fast image acquisition becomes critical
because the PDT treatment needs to be monitored in real-time without compromising the
detection quality in a clinical environment. Figure 1(b) shows the in vitro configuration to
characterize the system with deoxygenating capability. The camera viewed the solution
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samples within a few degrees of the direction of the excitation beam. To deoxygenate the
solution, nitrogen is slowly bubbled through a sample bottle. This deoxygenation method was
used to demonstrate that the near-IR camera measures the 1O2 phosphorescence even in the
presence of PS fluorescence.

Fig. 1. Singlet oxygen 2D imaging system. (a) The schematic of current 2D imaging system (in
vivo). (b) Experimental setup of deoxygenating configuration (in vitro).

A near-IR camera (MOSIR 950, 26.6 × 6.7 mm, 1024 × 256 pixels, 26 × 26 μm pixel size)
was used for the 1O2 phosphorescence detection. This camera uses a high quantum efficiency
photocathode and an electron bombardment intensifier to provide near single-photon detection
in the 1 to 1.5 μm spectral region. A visible camera (Pike F-145, 9.0 × 6.7 mm, 1392 × 1040
pixels, 6.45 × 6.45 μm pixel size) was used for the visible PS fluorescence measurement. To
image entire area of ~1 x 1 cm to the detector, the magnification of the imaging system was
set for × 0.57. Under these conditions, pixel resolution in the object plane is ~46 μm for the
near-IR image and ~12 μm for the visible image. The focal length of the dual beam imaging
system was 55 mm, and collimated light from the image area was split between the IR camera
and the visible camera through a beam-splitter.
For the BPD excitation, a fiber coupled diode laser with the wavelength centered at 692
nm was operated at a repetition rate of 10 kHz with a pulse width of 5 μs with an average
output power of ~230 mW during each pulse. Each pulse contained only 1.15 μJ. The beam
size of the excitation laser was 15 mm in diameter at the focal plane of the imager, and an
optical diffuser was used to generate a uniform excitation spot. At present, the time-gating
rate of the near-IR camera is insufficient for rapid data accumulation. Therefore, a non-gating
mode (continuous mode) for the near-IR camera with appropriate spectral background
subtraction was tested in this study. In the non-gating mode, the camera is focused on the
fluorescence volume and measures the collected photoelectrons for a preset length of time.
For the 1O2 detection, three spectral images were recorded in rapid succession using a
computer controlled slider containing three bandpass (BP) filters centered at 1.22, 1.27 and
1.32 µm, each with a full width at half maximum (FWHM) bandwidth of 15 nm. These filters
were used to spectrally isolate the 1O2 emission near 1.27 μm from the long wavelength
spectral background signal, such as PS fluorescence and/or phosphorescence, and
autofluorescence. The emissions at 1.22 and 1.32 µm (out-of-the band wavelengths) contain
only PS fluorescence while the emission at 1.27µm contains contributions from both the 1O2
and PS as shown in Fig. 2(a) obtained in vitro using BPD (1 μM in methanol). The images
recorded at 1.22 and 1.32 µm were co-registered and averaged to generate a single spectral
image of the PS fluorescence. This formed a first order estimate of the signal level of the PS
fluorescence contribution to the 1.27 µm image. This averaged PS fluorescence image was
subsequently subtracted on a pixel by pixel basis from the image obtained with the 1.27 µm
filter. For the visible PS fluorescence detection, a BP filter was selected and placed before the
visible CCD camera to transmit a specific wavelength region for the PS fluorescence. Each
bandpass filter was selected for a particular PS to optimize the transmission and spectral
discrimination.
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Fig. 2. Singlet oxygen detection method. (a) Temporal profiles (using PMT detector) of 1O2
phosphorescence at three bandpass filter positions with 1 μM BPD in methanol. The signal
during excitation light ON period (6-11 μs) is due primarily to PS fluorescence with 1320 and
1220 nm filter; or 1O2 emission and PS fluorescence with 1270 nm filter. The increase in the
signal with 1270 nm filter is due to increasing 1O2 production during the excitation pulse. (b)
Spectral features of 1O2 phosphorescence and total emission intensity with 1 μM BPD in
methanol. (c) The method of the 1O2 image process with the three-filter operation (in vitro).

To investigate the background signal level more precisely at and near the 1O2 emission
band, a liquid crystal tunable filter (Cambridge Research & Instrumentation, Inc., model#
LNIR-06, FWHM = 6 nm) was used to obtain a detailed spectrum. Figure 2(b) shows how the
long wavelength (1.2-1.4 µm) PS fluorescence is recorded and subtracted from the entire PDT
emission spectrum to provide the emission due to the 1O2. In the current 2D imaging system,
both 1O2 phosphorescence and PS fluorescence were collected, as shown in the upper trace of
the triangle symbols in Fig. 2(b) with three optical filters centered at 1.22, 1.27 and 1.32 μm.
The shaded areas under A, B, and C in Fig. 2(b) represent the total light intensities that were
measured for the out-of-the band baseline signals (A and C) and in-band signal of 1O2
intensity and baseline contribution (B). By subtracting the average baseline signal (average
value of A and C) from the signal B, the 1O2 intensity was calculated. This spectral
discrimination approach is essential to distinguish the 1O2 emission from other long
wavelength background signals, as mentioned above. Hu et al. measured the 2D images of 1O2
emission using a 1.27 μm optical filter with a long-pass filter (LP1150) [22]. As shown in Fig.
2(b), a single long-pass filter with a 1.27 μm filter is not able to robustly differentiate 1O2
phosphorescence from other long wavelength background signals. This is especially true for
in vivo measurements where the 1O2 phosphorescence is typically weak relative to the
underlying fluorescence background.
Figure 2(c) shows an example of how the images of 1O2 phosphorescence were acquired.
The diode laser beam was directed onto the face of a 1 cm square cuvette which contained 50
μM chlorine e6 (Cl-e6) in phosphate buffer solution. The pixel by pixel averaged values of the
1.22 and 1.32 µm images was subtracted from the image recorded at 1.27 µm to produce the
#142278 - $15.00 USD
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image of the 1O2 phosphorescence. Note that it takes typically less than 30 sec with in vitro
samples. In this example, dark count subtraction of each image before calculating the 1O2
intensity is not shown. The dark count subtraction for each image is an essential step to
improve S/N with in vivo image quality.
The spatial resolutions of both the visible and near-IR imaging systems were measured
using a standard Air Force test pattern as shown in Fig. 3. This imaging system was developed
to image the entire area of light illumination, ~1 × 1 cm. Therefore the magnification of the
imaging system considering physical size of detectors was optimized to image the entire area
to the detector as × 0.57 for both cameras. The respective spatial resolutions for the visible
and near-IR systems were <30 μm and <100 μm empirically estimated based on a FWHM
limit of a line spread function method.

Fig. 3. Image resolution of the dual-channel system. (a) Visible image. (b) NIR image.

2.2. In vitro and in vivo experiments
1

O2 phosphorescence imaging from BPD in methanol, water, FBS, and intralipid solutions
was investigated in order to determine the detection sensitivity. The solvents were used to
provide a variety of quenching environments. Since the lifetimes of 1O2 are known in these
solvents, they provided an excellent test of our system. BPD solutions were procured from
U.S. Pharmacopeia (Verteporfin) and solvents from Fisher Scientific. BPD concentrations
covering the range 10−4 to 10−6 molar were prepared. All mixed BPD solutions were kept in
amber glass bottles to minimize any interactions with room lights.
A preliminary study of 1O2 production during PDT in tumor laden mice was also
conducted. The BPD photosensitizer is commonly used for treatment of age related macular
degeneration [25], and has been initiated in studies for solid pancreatic tumors [26]. However,
the 1O2 generation of BPD is not as well studied as Cl-e6 or δ-aminoleuvulinic acid-induced
protoporphyrin IX (ALA-induced PpIX). We have previously reported results using these
latter photosensitizers [23,24]. All animal procedures were carried out according to protocols
approved by the Dartmouth College Institutional Animal Care and Use Committee (IACUC).
Pancreatic tumor cells were implanted subcutaneously in 6-week-old male nude mice (~22g).
AsPC-1 cells, derived from a human pancreatic acinar cell adenocarcinoma (CRL-1682,
American Type Culture Collection (ATCC), Manassas, VA 20108) were cultured in RPMI
1640 with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) penicillin-streptomycin prepared for
a stock solution of 10,000 IU penicillin and 10,000 g/ml streptomycin (Mediatech Herndon,
Virginia), 2mM L-glutamine, 10 mM HEPES, 1mM sodium pyruvate, 4500mg/L glucose, and
1500mg/L sodium bicarbonate. The cells were passed by washing twice with phosphate buffer
solution (PBS) without calcium and magnesium and then incubated at 37°C with 0.25%
trypsin for 5-10 minutes. When all the cells had lifted off from the bottom of the culture flask,
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the trypsin was neutralized with culture medium and the cell solution was pelleted and cells
suspended in complete medium at 4x107 cells/ml.
The cells, required for implantation, were prepared in a 1:1 mixture of cell culture medium
and Matrigel® (BD Biosciences, San Jose, CA). Matrigel® was thawed on ice in a 4°C
refrigerator overnight and was kept on ice for the entire implantation procedure. AsPC-1 cells
were diluted in a 1:1 ratio of culture medium and Matrigel® to a final concentration of 4x107
cells/ml for implantation. Sterile insulin syringes (1⁄2 cc U-100 Lo-Dose Insulin Syringe
281⁄2, Becton Dickinson & Co., Franklin Lakes, NJ) were loaded with the cell-Matrigel®
solution and placed and kept on ice ready for the implantation procedure.
Once the mouse was sedated using isoflurane gas (O2 flow meter set to 1L/min; induction
at 3% then reduced to 1.5-2%), the left side of the mouse’s abdomen was sterilized with an
iodine solution (Povidone-Iodine, Novaplus, Irving, TX) and the cell-Matrigel® solution
(1x106 cell in 50µl) was injected subcutaneously. The Matrigel® was allowed to set (~10
seconds) and the needle was gently removed from the injection site and swabbed with iodine
to kill any stray cells in the injection site. The growth of the AsPC-1 tumors in each mouse
was measured daily, using calipers, up to two weeks after implantation so that an average
tumor volume of approximately 90mm3 was reached for the in vivo BPD study.
BPD doses of 0.5, 1, and 2 mg / body weight kg were used for this part of the study.
Verteporfin for injection was obtained from QLT Inc. (Vancouver, Canada) as a gift.
Verteporfin for injection is composed of a sterile liposomal formulation of BPD-MA
(Visudyne, Novartis, New York). A stock saline solution of Verteporfin was reconstituted in
water according to the manufacturer’s guidelines, using 2.5% as the active component.
Animals were injected intravenously, via the lateral tail vein, with 75ul of Verteporfin to
achieve the required dose of 0.5, 1 or 2 mg/kg body weight.
After one hour to allow for systemic tissue distribution and uptake within the tissue
organs, the mouse was anesthetized for in vivo imaging. Gas anesthesia is the preferred
method of immobilization for in vivo imaging of mice and rats and isoflurane gas is minimally
metabolized (<0.17%) by the liver and therefore is less toxic to the animal’s metabolism as
compared to injectable anesthetics. Once the mouse was sedated, the skin around the tumor
was carefully cut and drawn back to expose the tumor tissue situated subcutaneously. The
mouse was transferred to the imaging platform of the dual-channel imaging system and placed
in position so that its nose was in front of the nose cone attached to the isoflurane anesthesia
system. The imaging system platform has an electric heat pad integrated in order to keep
animals warm during anesthesia in order to prevent hypothermia. Once the ideal position had
been achieved, images of BPD fluorescence and 1O2 phosphorescence were acquired using the
visible and near-IR cameras respectively. Each mouse took approximately 10 minutes to
image. After the tumor side was imaged, the skin on the contralateral side of the mouse was
removed and normal tissue was imaged for comparison. Following the completion of imaging,
the anesthetized mouse was euthanized by cervical dislocation.
3. Results and discussion
To characterize the imaging system, a series of in vitro studies were conducted with the BPD
photosensitizer in several media including protein-laden aqueous solutions that are significant
quenchers of 1O2. Figure 4(a) shows the spatially resolved images of both the 1O2
phosphorescence (right panel) and BPD fluorescence (left panel) in methanol recorded for 10
seconds through each of the three optical filters. To verify that this signal originates from 1O2,
nitrogen gas was bubbled through the sample bottle to displace the dissolved oxygen with the
configuration shown in Fig. 1(b). When the solution was deoxygenated as shown in Fig. 4(b),
the 1O2 phosphorescence signal diminished significantly. The intensities of the 1O2
phosphorescence and BPD fluorescence were summed within the illumination areas (marked
with a square box in the images) as shown in Fig. 4(c). The total photoelectron counts from
the 1O2 phosphorescence decreased more than 90% when the sample was deoxygenated. In
contrast, the BPD photosensitizer fluorescence remained essentially constant. These
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Fig. 4. Spatially resolved images (10 μM BPD in methanol). (a) Ambient air saturated. (b)
Deoxygenated solutions (nitrogen gas purging through the solution). (c) Total BPD
fluorescence and singlet O2 phosphorescence intensities in the area of the interest marked with
a square box in the images of 5 × 5 mm.

observations support our conclusion that the additional signal at 1270 nm we observed when
oxygen is present is from 1O2 phosphorescence.
Figure 5 shows the plot of both the 1O2 phosphorescence and BPD fluorescence intensities
(from spatially resolved images) as functions of the BPD concentration in a highly quenching
FBS environment. For comparison, the signal intensity of the 1O2 phosphorescence in 5% FBS
solutions was ~20 times lower than that in methanol solutions. These data were obtained in
40-50 seconds at each optical filter position to increase signal-to-noise level. There is a strong

Fig. 5. Plot of singlet O2 phosphorescence and BPD fluorescence as a function of BPD
concentration in 5% FBS with 5% TTX-100. Note that the intensities of PS fluorescence and
singlet O2 phosphorescence are not normalized with respect to the signal accumulation
conditions of the different camera settings.
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correlation between the PDT produced 1O2 and the PS fluorescence. Spatially resolved images
of the 1O2 phosphorescence and the PS fluorescence were obtained with the BPD
concentration as low as 500 nM (0.355 μg/ml) in FBS solution as well as in a highly scattering
environment using 2-5% intralipid solution. These concentrations are relevant to in vivo
applications and indicated that we might observe images of 1O2 phosphorescence in tumor
models. For comparison, a detection limit of 100 nM (0.071 μg/ml) was determined in
methanol solution (less quenching environment). These detection limits were determined with
the PS baseline subtraction to estimate 1O2 signal level.
Simultaneous, spatially resolved images were recorded for both the BPD fluorescence and
1
O2 phosphorescence with tumor laden mice. Both images from two mice with tumors
implanted are shown in Fig. 6 with 0.5 and 1 BPD mg/ body kg administered one hour prior to
imaging. We did not observe any selective localization of BPD photosensitizer in the AsPC-1
tumors vs. normal tissues, similar to that reported by O’Hara et al. [27]. These particular
images were recorded with the skin removed at the tumor sites. The BPD photosensitizer
accumulation in the AsPC-1 pancreatic model has been a challenge for these preliminary
experiments because of the lack of extensive vascular structure and considerable stroma
associated with this tumor model. The low concentration of BPD in tumor sites was confirmed
with separate BPD fluorescence measurements. Much stronger PS and 1O2 signals were
observed in earlier animal studies that we reported on, using Cl-e6 photosensitizer with
prostate tumor laden mice [23,24].
Even with a low 1O2 production condition caused by low BPD concentration in tumor
sites, we have obtained spatially correlated images of BPD fluorescence and 1O2
phosphorescence using our image data reduction algorithms described in the Methods section.
Some of the spatial features are common in both the PS and 1O2 images. In addition, the
spatial profiles of the intensities for the two species differ indicating that the 1O2 and PS
spatial profiles may be distinct. The noise in the near-IR 1O2 image is due to the relatively
small signal remaining subsequent to the data reduction algorithm that removes the near-IR
PS fluorescence background. Currently, we utilize a simple linear fit to estimate the PS
fluorescence baseline under the 1O2 phosphorescence spectral feature. However, the linear
baseline subtraction is clearly a first-order approximation. While this approximation appears
to work fairly well for lower quenching and scattering environments, we have seen
preliminary evidence that suggests this simple assumption may not be adequate with highly
quenching/scattering environments. For example, we observed that long wavelength

Fig. 6. Images of the BPD fluorescence and singlet oxygen phosphorescence from two tumor
laden mice. (a) 1.0 mg BPD / body kg. (b) 0.5 mg BPD / body kg.
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background signals in intralipid solutions are better fit with a non-linear polynomial function.
We will further investigate the long wavelength baseline component in this near-IR region to
improve the spectral discrimination method especially within in vivo environments. In
addition, once the system is optimized for PS fluorescence and 1O2 emission, our plan is to
calibrate the entire system using a blackbody source to determine its absolute spectral radiant
responsivity of each imaging channel. Recently, we also obtained spatially resolved images of
1
O2 phosphorescence and PS fluorescence using Cl-e6 with tumor laden mice in less than 3
minutes of data acquisition and these results will be reported in the near future.
4. Conclusion
We have described a dual-channel imaging system for simultaneous measurements of 1O2
phosphorescence and PS fluorescence for PDT. The current imaging system enabled direct
spatially resolved measurements of both the 1O2 and PS concentrations produced during PDT.
We performed sensitive in vitro measurements and obtained initial simultaneous images of the
1
O2 and PS from tumors in two mice. These results are promising for the development of a
real-time imaging dosimeter for PDT.
The 2D imaging system has the potential to facilitate a greater understanding of the
kinetics involved in PDT mechanisms, the relationship between 1O2 production and
photobleaching of the PS, and for developing more effective treatment modalities. An
accurate real-time dosimeter to characterize and optimize the individual treatment response of
PDT in a clinical environment would be an important tool to improve PDT efficacy. The dualchannel imaging system may enable us not only to target a specific area of PS in tumor sites
more precisely by monitoring PS fluorescence, but also to monitor the 1O2 production which
is an indication of tumor killing power during the PDT treatment. Eventually, it may even be
possible to measure the local singlet oxygen dose delivered to tissue during PDT and use such
dosimetry to improve therapeutic outcomes.
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